Aarti Drugs jump 5 per cent on robust Q3FY20 numbers
Aarti Drugs reported its financial numbers for the quarter ended December 31, 2019.
Its consolidated revenue for the quarter Q3FY20 came in at Rs 473.51 crore, as against Rs 380.11 crore in the corresponding quarter last year, registering 24.6 per cent YoY increase.
EBITDA for the quarter grew by 30.1 per cent YoY to Rs 67.49 crore as against Rs 51.86 crore in the corresponding quarter last year, with a corresponding margin expansion of 61 bps. EBITDA margin for the quarter stood at 14.3 per cent.
PAT for the quarter came in at Rs 27.78 crore as against Rs 20.89 crore in the corresponding quarter last year, YoY increase of 33 per cent.
Looking at nine-month numbers i.e. for 9MFY20, the revenue jumped by 23 per cent YoY to Rs 1,356.45 crore while, EBITDA grew by 26 per cent YoY to Rs 190.51 crore. Further, the company reported a net profit of Rs 82.54 crore, up by 32 per cent, YoY.
The board of directors has declared the interim dividend of Rs 2 per equity share (face value Rs 10) for the financial year 2019-20.
Today, the stock witnessed a gap-up opening by three per cent at Rs 645 and gained nearly five per cent to touch an intraday high of Rs 657 on BSE.